FDA Approves T-DXd + Pertuzumab for HER2+
Breakthrough Alert: T-DXd/Pertuzumab Earns FDA Approval for Advanced HER2+ Breast Cancer Treatment Key Takeaways Game-Changer for Patients: The FDA’s recent approval of T-DXd (Enhertu) combined…
Newsroom
Category: Uncategorized
Oracle Stock: Buy the Dip After Q2 Shock?
Is Oracle Stock (ORCL) a Buy After the Latest Earnings Shock? Oracle’s cloud business is exploding: Revenue hit $8 billion in Q2 FY2026, up 34%…
Mutual Funds: 26% Returns but 2% Fees—Fair?
‘Is This Fair?’ Mutual Funds with a Broker Earning 26% Returns But Charging 2% Fees: Is It a Worthwhile Tradeoff? Key Takeaways High fees can…
US Halts UK Tech Deal Talks: FT Report
U.S. Halts UK Tech Trade Deal Negotiations: FT Reports on a Major Setback for Global Innovation Key Takeaways Sudden Pause in Talks: The U.S. has…
Markets This Week: Jobs, Inflation & Earnings
What to Expect in Markets This Week: Jobs Report, Inflation Data, and Earnings from Micron, Nike, and FedEx Key Takeaways Jobs Report on Deck: The…
Earnings Week Ahead: FDX, NKE, MU & More
Earnings Week Ahead: FDX, NKE, MU, BB, CCL, ACN, and More – Key Insights for December 2025 Investors